FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Biller Jonathan (Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC.					2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS, INC. [AGIO] 3. Date of Earliest Transaction (Month/Day/Year) 12/03/2019							Directo Officer below)	ationship of Reporting Person(s) to Isk all applicable) Director 10% C Officer (give title below) Chief Legal Officer			ner	
88 SIDNEY STREET (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						ction 2A. Deemed Execution Date,			4. Secu	Securities Acquired (A) isposed Of (D) (Instr. 3, 4		5. Amount of Securities Beneficially (D)		6. Owne Form: D (D) or Ir (I) (Instr	Direct condirect E r. 4) C	7. Nature of Indirect Beneficial Dwnership Instr. 4)	
(e.g., pu 1. Title of				y, puts,	ansaction of ode (Instr. Derivative				convert	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly O	0. Ownership orm: Orect (D) or Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock option (right to buy)	\$39.11	12/03/2019		A		78,824		(1)	12/03/2029	Common stock	78,824	\$0	78,824	1	D		
Restricted stock units	(2)	12/03/2019		A		17,259		(3)	(3)	Common stock	17,259	\$0	17,259	9	D		

Explanation of Responses:

- 1. This option was granted on December 3, 2019. The shares underlying this option vest as to 25% of the underlying shares on December 3, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- 2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- 3. The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.

Remarks:

/s/ William Cook, as Attorney in Fact for Jonathan Biller

12/05/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.